| abstract |
Disclosed are compounds of formula I, wherein R1 is 1,4-dioxepanyl or tetrahydropyran-4-yl and the remaining substituents are as defined in the specification. The compounds are adenosine A2A receptor ligands useful in the treatment of diseases of the central nervous system including Alzheimer's disease, depression, drug addiction, neuroprotection, Parkinson's disease or attention deficit hyperactivity disorder (ADHD). |